Mark Noviski

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Skye Montoya, Jessie Bourcier, Mark Noviski et al. · Science · 2024 · 129 citations · Full text

Engineering, Mixed-phenotype Acute Leukemia, Genetics +17

IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate

Mark Noviski, James L. Mueller, Anne B. Satterthwaite et al. · eLife · 2018 · 95 citations · Full text

NR4A nuclear receptors restrain B cell responses to antigen when second signals are absent or limiting

Corey Tan, Ryosuke Hiwa, James L. Mueller et al. · Nature Immunology · 2020 · 89 citations · Full text

B Cell Responses, Signal Transduction, Adaptive Immune System +11

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Daniel Robbins, Mark Noviski, Ying Siow Tan et al. · Journal of Medicinal Chemistry · 2024 · 78 citations · Full text

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Daniel Robbins, Aileen Kelly, May Tan et al. · Blood · 2020 · 45 citations